Heparin Solution and INTEM/HEPTEM Analysis
This study is currently recruiting participants.
Verified January 2012 by Seoul National University Bundang Hospital
Information provided by (Responsible Party):
Hyo-Seok Na, Seoul National University Bundang Hospital
First received: January 9, 2012
Last updated: January 27, 2012
Last verified: January 2012
Heparinized solution has been used for maintenance of arterial catheter during perioperative period. Although the infused dose of heparin is very low, the investigators examine whether the heparin effect is remained or not in blood using rotational thromboelastometry (ROTEM) analysis.
Cerebral Artery Anuerysm
||Observational Model: Case-Only
Time Perspective: Prospective
||Influence by Heparinized Flush Solution of the Radial Artery Catheter: INTEM and HEPTEM Analysis.
Primary Outcome Measures:
- INTEM test [ Time Frame: at 30 min before operation and 30 min after operation ] [ Designated as safety issue: No ]
INTEM is not an abbriviation. INTEM is one of the ROTEM test and it is an coagulation test name (such as prothrombin time test) using patient's whole blood. We put the blood sample of patinet into the machine, so the result comes out automatically. It will be checked twice at pre- and postopertive 30 minute and it'll be analyzed and compared.
- HEPTEM test [ Time Frame: at 30 min before operation and 30 min after operation ] [ Designated as safety issue: No ]
HEPTEM is not an abbriviation. HEPTEM is one of the ROTEM test and it is an coagulation test name (such as prothrombin time test) using patient's whole blood. We put the blood sample of patinet into the machine, so the result comes out automatically. It will be checked twice at pre- and postopertive 30 minute and it'll be analyzed and compared.
Secondary Outcome Measures:
- Total infused units of heparin [ Time Frame: periond from starting operation to finishing operation (espected average of 5 hours). ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||January 2013 (Final data collection date for primary outcome measure)
Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
|Ages Eligible for Study:
||20 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients requiring continuous invasive arterial pressure monitoring during operation for anesthetic management.
- Patients requiring continuous invasive arterial pressure monitoring during operation for anesthetic management.
- heparin hypersensitivity
- hematologic disease
- anticoagulant medication
Please refer to this study by its ClinicalTrials.gov identifier: NCT01522846
|Seoul National University Bundang Hospital
|Seonnam, Gyounggi, Korea, Republic of, 463-707 |
|Contact: Hyo-Seok Na, professor` 82-31-787-7507 firstname.lastname@example.org |
|Principal Investigator: Hyo-Seok Na, Professor |
Seoul National University Bundang Hospital
No publications provided
||Hyo-Seok Na, Assistant professor, Seoul National University Bundang Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||January 9, 2012
||January 27, 2012
||South Korea: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 23, 2013
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Central Nervous System Diseases
Nervous System Diseases
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action